.jeffrey krasner is president of emerging biocommunications, which consults to early- and mid-stage life science companies..for advertisers.. 0....eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention. https://oakley-sunglassesformen.us/Fiely-son-of-Meininger-from-Slobozia?Mulryanbr=85 ... we value our readers and are committed to growing our community by encouraging you to add to the discussion.. september 2017 (21).. tam - ????? .